{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:32:48Z","timestamp":1790389968697,"version":"4.1.0"},"reference-count":225,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":394,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/R013764\/1"],"award-info":[{"award-number":["EP\/R013764\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,30]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Since the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some approaches that have not previously been licensed for human vaccines. Vaccines have been widely considered as part of the exit strategy to enable the return to previous patterns of working, schooling and socializing. Importantly, to effectively control the COVID-19 pandemic, production needs to be scaled-up from a small number of preclinical doses to enough filled vials to immunize the world's population, which requires close engagement with manufacturers and regulators. It will require a global effort to control the virus, necessitating equitable access for all countries to effective vaccines. This review explores the immune responses required to protect against SARS-CoV-2 and the potential for vaccine-induced immunopathology. We describe the profile of the different platforms and the advantages and disadvantages of each approach. The review also addresses the critical steps between promising preclinical leads and manufacturing at scale. The issues faced during this pandemic and the platforms being developed to address it will be invaluable for future outbreak control. Nine months after the outbreak began we are at a point where preclinical and early clinical data are being generated for the vaccines; an overview of this important area will help our understanding of the next phases.<\/jats:p>","DOI":"10.1111\/cei.13517","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T18:19:34Z","timestamp":1600366774000},"page":"162-192","source":"Crossref","is-referenced-by-count":202,"title":["Vaccines for COVID-19"],"prefix":"10.1093","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-8741","authenticated-orcid":false,"given":"J S","family":"Tregoning","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E S","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-1341","authenticated-orcid":false,"given":"H M","family":"Cheeseman","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-6864","authenticated-orcid":false,"given":"K E","family":"Flight","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4139-7780","authenticated-orcid":false,"given":"S L","family":"Higham","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N-M","family":"Lemm","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-5201","authenticated-orcid":false,"given":"B F","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-7161","authenticated-orcid":false,"given":"D C","family":"Stirling","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1110-808X","authenticated-orcid":false,"given":"Z","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9513-5183","authenticated-orcid":false,"given":"K M","family":"Pollock","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St Mary's Campus, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,18]]},"reference":[{"key":"2021121023214865000_cei13517-bib-0001","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"2021121023214865000_cei13517-bib-0002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol J"},{"key":"2021121023214865000_cei13517-bib-0003","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"2021121023214865000_cei13517-bib-0004","article-title":"The SARS-CoV-2 spike protein has a broad tropism for mammalian ACE2 proteins","author":"Conceicao","year":"2020","journal-title":"bioRxiv"},{"key":"2021121023214865000_cei13517-bib-0005","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed Asymptomatic Carrier Transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"JAMA"},{"key":"2021121023214865000_cei13517-bib-0006","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41591-020-0916-2","article-title":"Real-time tracking of self-reported symptoms to predict potential COVID-19","volume":"26","author":"Menni","year":"2020","journal-title":"Nat Med"},{"key":"2021121023214865000_cei13517-bib-0007","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1001\/jama.2020.6771","article-title":"Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection","volume":"323","author":"Spinato","year":"2020","journal-title":"JAMA, J Am Med Assocs"},{"key":"2021121023214865000_cei13517-bib-0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"2021121023214865000_cei13517-bib-0009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"OpenSAFELY: factors associated with COVID-19 death in 17 million patients","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"2021121023214865000_cei13517-bib-0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","article-title":"Lessons for COVID-19 Immunity from Other Coronavirus Infections","volume":"53","author":"Sariol","year":"2020","journal-title":"Immunity"},{"key":"2021121023214865000_cei13517-bib-0011","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","article-title":"T cell responses in patients with COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2021121023214865000_cei13517-bib-0012","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/JVI.01281-09","article-title":"Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB\/c mice: CD4+ T cells are important in control of SARS-CoV infection","volume":"84","author":"Chen","year":"2010","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0013","article-title":"How immune T-cell augmentation can help prevent COVID-19: a possible nutritional solution using ketogenic lifestyle","volume":"4","author":"Kamepalli","year":"2020","journal-title":"Univ Louisville J Respir Infect"},{"key":"2021121023214865000_cei13517-bib-0014","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1128\/JVI.01049-10","article-title":"T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice","volume":"84","author":"Zhao","year":"2010","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0015","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.1128\/JVI.01505-14","article-title":"Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection","volume":"88","author":"Channappanavar","year":"2014","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0016","first-page":"1093","article-title":"Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection","volume":"154","author":"Fan","year":"2009","journal-title":"Adv Virol"},{"key":"2021121023214865000_cei13517-bib-0017","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"2021121023214865000_cei13517-bib-0018","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume-title":"Cell","author":"Sekine","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0019","article-title":"Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion","author":"Gallais","year":"2020","journal-title":"medRxiv"},{"key":"2021121023214865000_cei13517-bib-0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/imm.13223","article-title":"Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China","volume":"160","author":"Tan","year":"2020","journal-title":"Immunology"},{"key":"2021121023214865000_cei13517-bib-0021","article-title":"Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors","volume-title":"Nature","author":"Braun","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0022","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The potential role of TH17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement: Elsevier","volume":"22","author":"Hotez","year":"2020","journal-title":"Microbes Infect"},{"key":"2021121023214865000_cei13517-bib-0023","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"2021121023214865000_cei13517-bib-0024","doi-asserted-by":"crossref","DOI":"10.1101\/2020.03.23.20040675","article-title":"Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2","volume-title":"medRxiv","author":"Yang","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0025","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1086\/500469","article-title":"Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome","volume":"193","author":"Liu","year":"2006","journal-title":"J Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0026","doi-asserted-by":"crossref","first-page":"m1724","DOI":"10.1136\/bmj.m1724","article-title":"Persistence of viral RNA in stool samples from patients recovering from COVID-19","volume":"369","author":"Barth","year":"2020","journal-title":"BMJ"},{"key":"2021121023214865000_cei13517-bib-0027","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1073\/pnas.0307140101","article-title":"Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association","volume":"101","author":"Sui","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021121023214865000_cei13517-bib-0028","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1469-0691.2004.01009.x","article-title":"Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus","volume":"10","author":"Hsueh","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2021121023214865000_cei13517-bib-0029","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3201\/eid2112.151421","article-title":"Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea","volume":"21","author":"Park","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0030","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/ptj\/49.7.763","article-title":"Converting detachable wheelchair armrests into parallel bars","volume":"49","author":"Presty","year":"1969","journal-title":"Phys Ther"},{"key":"2021121023214865000_cei13517-bib-0031","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJMoa1405858","article-title":"Transmission of MERS-coronavirus in household contacts","volume":"371","author":"Drosten","year":"2014","journal-title":"NEJM"},{"key":"2021121023214865000_cei13517-bib-0032","article-title":"A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease","author":"Huang","year":"2020","journal-title":"medRxiv"},{"key":"2021121023214865000_cei13517-bib-0033","article-title":"Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection","author":"Seow","year":"2020","journal-title":"medRxiv"},{"key":"2021121023214865000_cei13517-bib-0034","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/S0950268800048019","article-title":"The time course of the immune response to experimental coronavirus infection of man","volume":"105","author":"Callow","year":"1990","journal-title":"Epidemiol Infect"},{"key":"2021121023214865000_cei13517-bib-0035","article-title":"COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing","author":"To","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0036","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3680955","article-title":"Genomic evidence for a case of reinfection with SARS-CoV-2","volume-title":"Lancet","author":"Tillet","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0037","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jgg.2020.01.003","article-title":"Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus","volume":"47","author":"Qiu","year":"2020","journal-title":"J Genet Genomics"},{"key":"2021121023214865000_cei13517-bib-0038","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2021121023214865000_cei13517-bib-0039","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","article-title":"Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation","volume":"53","author":"Seydoux","year":"2020","journal-title":"Immunity"},{"key":"2021121023214865000_cei13517-bib-0040","volume-title":"Physiology, Antibody in StatsPearls","author":"Aziz","year":"2019"},{"key":"2021121023214865000_cei13517-bib-0041","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools","volume":"35","author":"Fu","year":"2020","journal-title":"Virol Sinica"},{"key":"2021121023214865000_cei13517-bib-0042","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The role of IgA in COVID-19","volume":"87","author":"Chao","year":"2020","journal-title":"Brain Behav Immun"},{"key":"2021121023214865000_cei13517-bib-0043","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain\u2013Barr\u00e9 syndrome following vaccination in the national influenza immunization program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"2021121023214865000_cei13517-bib-0044","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2016.10.60","article-title":"Narcolepsy and influenza vaccination\u2014the inappropriate awakening of immunity","volume":"4","author":"Nellore","year":"2016","journal-title":"Ann Transl Med"},{"key":"2021121023214865000_cei13517-bib-0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbi.2014.11.004","article-title":"Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development","volume":"47","author":"Jacob","year":"2015","journal-title":"Brain Behav Immun"},{"key":"2021121023214865000_cei13517-bib-0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114361","article-title":"Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk","volume":"9","author":"Vaarala","year":"2014","journal-title":"PLOS ONE"},{"key":"2021121023214865000_cei13517-bib-0047","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab2354","article-title":"Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2","volume":"7","author":"Ahmed","year":"2015","journal-title":"Sci Transl Med"},{"key":"2021121023214865000_cei13517-bib-0048","volume-title":"Statement on narcolepsy and vaccination","author":"World Health Organization","year":"2011"},{"key":"2021121023214865000_cei13517-bib-0049","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archpedi.1965.02090020234007","article-title":"Measles immunization with killed virus vaccine: serum antibody titers and experience with exposure to measles epidemic","volume":"109","author":"Rauh","year":"1965","journal-title":"Am J Dis Child"},{"key":"2021121023214865000_cei13517-bib-0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"2021121023214865000_cei13517-bib-0051","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"2021121023214865000_cei13517-bib-0052","article-title":"Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein","volume":"13","author":"Kim","year":"2018","journal-title":"PLOS ONE"},{"key":"2021121023214865000_cei13517-bib-0053","article-title":"Alum adjuvant enhances protection against respiratory syncytial virus but exacerbates pulmonary inflammation by modulating multiple innate and adaptive immune cells","volume":"10","author":"Kim","year":"2015","journal-title":"PLOS ONE"},{"key":"2021121023214865000_cei13517-bib-0054","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1080\/21645515.2015.1075680","article-title":"Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats","volume":"11","author":"O'Konek","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2021121023214865000_cei13517-bib-0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nri2887","article-title":"Mechanisms for T cell receptor triggering","volume":"11","author":"Van Der Merwe","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2021121023214865000_cei13517-bib-0056","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2021121023214865000_cei13517-bib-0057","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nri3014","article-title":"Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms","volume":"11","author":"Rothman","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2021121023214865000_cei13517-bib-0058","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nm1456","article-title":"A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines","volume":"12","author":"Moghaddam","year":"2006","journal-title":"Nat Med"},{"key":"2021121023214865000_cei13517-bib-0059","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7883\/yoken.JJID.2007.106","article-title":"Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses","volume":"60","author":"Tsunetsugu-Yokota","year":"2007","journal-title":"Jpn J Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0060","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1016\/j.vaccine.2018.05.093","article-title":"Examination of the effects of virus inactivation methods on the induction of antibody-and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens","volume":"36","author":"Astill","year":"2018","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0061","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/CMR.18.3.541-555.2005","article-title":"Immune responses and disease enhancement during respiratory syncytial virus infection","volume":"18","author":"Openshaw","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2021121023214865000_cei13517-bib-0062","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.aaz9447","article-title":"Vaccination strategies to enhance immunity in neonates","volume":"368","author":"Kollmann","year":"2020","journal-title":"Science"},{"key":"2021121023214865000_cei13517-bib-0063","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.vaccine.2008.10.087","article-title":"Vaccine-induced enhancement of viral infections","volume":"27","author":"Huisman","year":"2009","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0064","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nri1732","article-title":"Immunopathogenesis of coronavirus infections: implications for SARS","volume":"5","author":"Dandekar","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2021121023214865000_cei13517-bib-0065","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"key":"2021121023214865000_cei13517-bib-0066","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1084\/jem.146.1.218","article-title":"Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection","volume":"146","author":"Halstead","year":"1977","journal-title":"J Exp Med"},{"key":"2021121023214865000_cei13517-bib-0067","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri3916","article-title":"New insights into the immunopathology and control of dengue virus infection","volume":"15","author":"Screaton","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2021121023214865000_cei13517-bib-0068","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"key":"2021121023214865000_cei13517-bib-0069","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLOS ONE"},{"key":"2021121023214865000_cei13517-bib-0070","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","article-title":"Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets","volume":"78","author":"Weingartl","year":"2004","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0071","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti\u2013spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"2021121023214865000_cei13517-bib-0072","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0073","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"2021121023214865000_cei13517-bib-0074","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.tim.2006.05.007","article-title":"Is there an ideal animal model for SARS?","volume":"14","author":"Subbarao","year":"2006","journal-title":"Trends Microbiol"},{"key":"2021121023214865000_cei13517-bib-0075","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.96.14.7797","article-title":"Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase","volume":"96","author":"Rao","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021121023214865000_cei13517-bib-0076","doi-asserted-by":"crossref","DOI":"10.1126\/science.303.5660.944","volume-title":"Caution urged on SARS vaccines: American Association for the Advancement of Science","author":"Marshall","year":"2004"},{"key":"2021121023214865000_cei13517-bib-0077","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1128\/JVI.79.9.5833-5838.2005","article-title":"Aged BALB\/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans","volume":"79","author":"Roberts","year":"2005","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0078","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0079","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.virol.2015.02.030","article-title":"Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus","volume":"479","author":"Sutton","year":"2015","journal-title":"Virology"},{"key":"2021121023214865000_cei13517-bib-0080","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1080\/22221751.2019.1685912","article-title":"Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein","volume":"8","author":"Rodon","year":"2019","journal-title":"Emerg Microb Infect"},{"key":"2021121023214865000_cei13517-bib-0081","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-52730-4","article-title":"Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels","volume":"9","author":"Alharbi","year":"2019","journal-title":"Sci Rep"},{"key":"2021121023214865000_cei13517-bib-0082","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"2021121023214865000_cei13517-bib-0083","doi-asserted-by":"crossref","first-page":"2001005","DOI":"10.2807\/1560-7917.ES.2020.25.23.2001005","article-title":"SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020","volume":"25","author":"Oreshkova","year":"2020","journal-title":"Eurosurveillance"},{"key":"2021121023214865000_cei13517-bib-0084","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS\u2013coronavirus 2","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"key":"2021121023214865000_cei13517-bib-0085","article-title":"Reinfection could not occur in SARS-CoV-2 infected rhesus macaques","volume-title":"BioRxiv","author":"Bao","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0086","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/medethics-2020-106322","article-title":"Ethical guidelines for deliberately infecting volunteers with COVID-19","volume":"46","author":"Richards","year":"2020","journal-title":"J Med Ethics"},{"key":"2021121023214865000_cei13517-bib-0087","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/infdis\/jiaa152","article-title":"Human challenge studies to accelerate coronavirus vaccine licensure","volume":"221","author":"Eyal","year":"2020","journal-title":"J Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2020.08.006","article-title":"SARS-CoV-2 controlled human infection models: ethics, challenge agent production and regulatory issues","volume-title":"Biologicals","author":"Baay","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0089","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19. Preliminary report","author":"Horby","year":"2020","journal-title":"medRxiv"},{"key":"2021121023214865000_cei13517-bib-0090","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"2021121023214865000_cei13517-bib-0091","volume-title":"Key criteria for the ethical acceptability of COVID-19 human challenge studies","author":"World Health Organization","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0092","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1056\/NEJMp2020076","article-title":"Accelerating development of SARS-CoV-2 vaccines \u2013 the role for controlled human infection models","volume":"383","author":"Deming","year":"2020","journal-title":"N Engl J Med"},{"key":"2021121023214865000_cei13517-bib-0093","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2018.05.007","article-title":"Vaccination-induced herd immunity: successes and challenges","volume":"142","author":"Mallory","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2021121023214865000_cei13517-bib-0094","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1080\/21645515.2015.1052196","article-title":"Dissecting the indirect effects caused by vaccines into the basic elements","volume":"11","author":"Scarbrough Lefebvre","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2021121023214865000_cei13517-bib-0095","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41423-020-0385-z","article-title":"Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2021121023214865000_cei13517-bib-0096","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41594-019-0233-y","article-title":"Structural basis for human coronavirus attachment to sialic acid receptors","volume":"26","author":"Tortorici","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"2021121023214865000_cei13517-bib-0097","article-title":"Emergence of SARS-CoV-2 through recombination and strong purifying selection","author":"Li","year":"2020","journal-title":"Sci Adv"},{"key":"2021121023214865000_cei13517-bib-0098","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2021121023214865000_cei13517-bib-0099","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"2021121023214865000_cei13517-bib-0100","article-title":"Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates","volume":"15","author":"Liu","year":"2020","journal-title":"PLOS ONE"},{"key":"2021121023214865000_cei13517-bib-0101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128779","article-title":"A cysteine zipper stabilizes a pre-fusion F glycoprotein vaccine for respiratory syncytial virus","volume":"10","author":"Stewart-Jones","year":"2015","journal-title":"PLOS ONE"},{"key":"2021121023214865000_cei13517-bib-0102","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jviromet.2004.04.009","article-title":"Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus","volume":"120","author":"Berry","year":"2004","journal-title":"J Virol Methods"},{"key":"2021121023214865000_cei13517-bib-0103","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat Commun"},{"key":"2021121023214865000_cei13517-bib-0104","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1743-422X-7-99","article-title":"Interactions of SARS coronavirus nucleocapsid protein with the host cell proteasome subunit p42","volume":"7","author":"Wang","year":"2010","journal-title":"Virol J"},{"key":"2021121023214865000_cei13517-bib-0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12026-014-8534-z","article-title":"T cell-mediated immune response to respiratory coronaviruses","volume":"59","author":"Channappanavar","year":"2014","journal-title":"Immunol Res"},{"key":"2021121023214865000_cei13517-bib-0106","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"key":"2021121023214865000_cei13517-bib-0107","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1586\/erv.12.65","article-title":"Influenza vaccines and immunopathology","volume":"11","author":"Gilbert","year":"2012","journal-title":"Expert Rev Vaccin"},{"key":"2021121023214865000_cei13517-bib-0108","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s10038-020-0771-5","article-title":"Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2","volume":"65","author":"Kiyotani","year":"2020","journal-title":"J Hum Genet"},{"key":"2021121023214865000_cei13517-bib-0109","volume-title":"DRAFT landscape of COVID-19 candidate vaccines","author":"World Health Organization","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent advances in the production of recombinant subunit vaccines in Pichia pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"2021121023214865000_cei13517-bib-0111","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"2021121023214865000_cei13517-bib-0112","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/19420862.2016.1267088","article-title":"Optimizing assembly and production of native bispecific antibodies by codon de-optimization","volume":"9","author":"Magistrelli","year":"2017","journal-title":"MAbs"},{"key":"2021121023214865000_cei13517-bib-0113","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/21645515.2015.1021527","article-title":"Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus","volume":"11","author":"Tang","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2021121023214865000_cei13517-bib-0114","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1128\/JVI.01277-13","article-title":"The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies","volume":"87","author":"Mou","year":"2013","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0115","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","article-title":"Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments\u2014the importance of immunofocusing in subunit vaccine design","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0116","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1128\/JVI.79.6.3289-3296.2005","article-title":"Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents","volume":"79","author":"Keng","year":"2005","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0117","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1073\/pnas.0503760102","article-title":"Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine","volume":"102","author":"Pogrebnyak","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021121023214865000_cei13517-bib-0118","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.4049\/jimmunol.174.8.4908","article-title":"Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies","volume":"174","author":"He","year":"2005","journal-title":"J Immunol"},{"key":"2021121023214865000_cei13517-bib-0119","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2014.02.004","article-title":"Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0120","volume-title":"Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Wuhan Coronavirus (2019-nCoV)","author":"PipelineReview","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0121","volume-title":"Clover successfully produced 2019-nCoV subunit vaccine candidate and detected cross-reacting antibodies from sera of multiple infected patients","author":"PipelineReview","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0122","doi-asserted-by":"crossref","DOI":"10.1038\/d41587-020-00005-z","volume-title":"The pandemic pipeline","author":"Hodgson","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0123","volume-title":"Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19","author":"GSK","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0124","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1134\/S0026893319030154","article-title":"Virus-like particles as an instrument of vaccine production","volume":"53","author":"Syomin","year":"2019","journal-title":"Mol Biol"},{"key":"2021121023214865000_cei13517-bib-0125","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bbrc.2004.04.111","article-title":"Assembly of human severe acute respiratory syndrome coronavirus-like particles","volume":"318","author":"Ho","year":"2004","journal-title":"Biochem Biophys Res Comm"},{"key":"2021121023214865000_cei13517-bib-0126","volume-title":"Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development","author":"Novavax","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0127","volume-title":"Novavax Recombinant Protein Nanoparticle Vaccine Technology","author":"Novavax","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0128","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume-title":"NEJM","author":"Keech","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0129","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice","author":"Tian","year":"2020","journal-title":"bioRxiv"},{"key":"2021121023214865000_cei13517-bib-0130","volume-title":"COVID-19: Medicago's Development Programs. 2020 Medicago","author":"Medicago","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0131","article-title":"Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles","volume-title":"bioRxiv","author":"Zha","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0132","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1099\/00222615-39-4-241","article-title":"Synthetic peptide vaccines","volume":"39","author":"Sesardic","year":"1993","journal-title":"J Med Microbiol"},{"key":"2021121023214865000_cei13517-bib-0133","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/14760584.6.4.591","article-title":"Design and development of synthetic peptide vaccines: past, present and future","volume":"6","author":"Bijker","year":"2007","journal-title":"Expert Rev Vaccin"},{"key":"2021121023214865000_cei13517-bib-0134","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1074\/jbc.M809456200","article-title":"Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells","volume":"284","author":"Zhang","year":"2009","journal-title":"J Biol Chem"},{"key":"2021121023214865000_cei13517-bib-0135","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/eji.201343324","article-title":"Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation","volume":"43","author":"Rosalia","year":"2013","journal-title":"Eur J Immunol"},{"key":"2021121023214865000_cei13517-bib-0136","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design","volume":"6","author":"Purcell","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"2021121023214865000_cei13517-bib-0137","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines"},{"key":"2021121023214865000_cei13517-bib-0138","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/v12030254","article-title":"Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"key":"2021121023214865000_cei13517-bib-0139","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jmv.25736","article-title":"Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach","volume":"92","author":"Bhattacharya","year":"2020","journal-title":"J Med Virol"},{"key":"2021121023214865000_cei13517-bib-0140","first-page":"2020050519","volume-title":"Molecular and Structural Insights into COVID-19 Pandemic","author":"Kadam","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104236","article-title":"Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2","volume":"145","author":"Kalita","year":"2020","journal-title":"Microb Pathog"},{"key":"2021121023214865000_cei13517-bib-0142","article-title":"Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine","author":"Gauttier","year":"2020","journal-title":"bioRxiv"},{"key":"2021121023214865000_cei13517-bib-0143","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01081","article-title":"HLA-class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy","volume":"10","author":"Couture","year":"2019","journal-title":"Front Immunol"},{"key":"2021121023214865000_cei13517-bib-0144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-020-0188-3","article-title":"COVID-19 vaccines: breaking record times to first-in-human trials","volume":"5","author":"Kim","year":"2020","journal-title":"NPJ Vaccin"},{"key":"2021121023214865000_cei13517-bib-0145","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-018-0056-7","article-title":"Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus","volume":"7","author":"Deng","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"2021121023214865000_cei13517-bib-0147","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.vaccine.2005.06.038","article-title":"Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine","volume":"24","author":"Qin","year":"2006","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0148","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"6499","author":"Gao","year":"2020","journal-title":"Science"},{"key":"2021121023214865000_cei13517-bib-0149","article-title":"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: report of the randomized, double-blind, and placebo-controlled Phase 2 clinical trial","author":"Zhang","year":"2020","journal-title":"medRxiv"},{"key":"2021121023214865000_cei13517-bib-0150","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"2021121023214865000_cei13517-bib-0151","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1016\/j.vaccine.2015.05.103","article-title":"Influence of elemental impurities in aluminum hydroxide adjuvant on the stability of inactivated Japanese Encephalitis vaccine, IXIARO\u00ae","volume":"33","author":"Schlegl","year":"2015","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0152","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent advances in the vaccine development against middle east respiratory syndrome \u2013 coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front Microbiol"},{"key":"2021121023214865000_cei13517-bib-0153","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/S0264-410X(01)00045-7","article-title":"Live attenuated vaccines against influenza; an historical review","volume":"19","author":"Wareing","year":"2001","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0154","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1128\/JVI.03566-14","article-title":"Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates","volume":"89","author":"Regla-Nava","year":"2015","journal-title":"J Virol"},{"key":"2021121023214865000_cei13517-bib-0155","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00650-13","article-title":"Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate","volume":"4","author":"Almaz\u00e1n","year":"2013","journal-title":"mBio"},{"key":"2021121023214865000_cei13517-bib-0156","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2020.02.056","article-title":"A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates","volume":"38","author":"Mueller","year":"2020","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0157","volume-title":"Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19","author":"BioSpace","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0158","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7774\/cevr.2013.2.2.97","article-title":"Viral vectors for vaccine applications","volume":"2","author":"Choi","year":"2013","journal-title":"Clin Exp Vaccin Res"},{"key":"2021121023214865000_cei13517-bib-0159","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","article-title":"Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice","volume":"101","author":"Bisht","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021121023214865000_cei13517-bib-0160","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0161","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"key":"2021121023214865000_cei13517-bib-0162","article-title":"Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19","author":"Graham","year":"2020","journal-title":"bioRxiv"},{"key":"2021121023214865000_cei13517-bib-0163","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume-title":"Nature","author":"van Doremalen","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0164","doi-asserted-by":"crossref","DOI":"10.1101\/2020.05.13.093195","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","volume-title":"bioRxiv","author":"van Doremalen","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0165","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"2021121023214865000_cei13517-bib-0166","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2021121023214865000_cei13517-bib-0167","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2021121023214865000_cei13517-bib-0168","volume-title":"Patented Technologies to Advance Disease Research","author":"Janssen","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0169","volume-title":"Johnson & Johnson Receives Positive CHMP Opinion for Janssen's Investigational Preventive Ebola Vaccine Regimen","author":"Businesswire","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0170","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume-title":"Nature","author":"Mercado","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0171","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume-title":"Lancet","author":"Logunov","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0172","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0173","volume-title":"MIGAL's Coronavirus Vaccine Project","author":"Migal","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0174","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.PLAS-0028-2014","article-title":"Using plasmids as DNA vaccines for infectious diseases","volume":"2","author":"Tregoning","year":"2014","journal-title":"Microbiol Spectr"},{"key":"2021121023214865000_cei13517-bib-0175","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.188.6.1075","article-title":"Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization","volume":"188","author":"Porgador","year":"1998","journal-title":"J Exp Med"},{"key":"2021121023214865000_cei13517-bib-0176","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"2021121023214865000_cei13517-bib-0177","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-065X.2008.00718.x","article-title":"Inflammatory signals in dendritic cell activation and the induction of adaptive immunity","volume":"227","author":"Joffre","year":"2009","journal-title":"Immunol Rev"},{"key":"2021121023214865000_cei13517-bib-0178","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF02976869","article-title":"In vivo kinetics and biodistribution of a HIV-1 DNA vaccine after administration in mice","volume":"26","author":"Kim","year":"2003","journal-title":"Arch Pharm Res"},{"key":"2021121023214865000_cei13517-bib-0179","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0092-8674(80)90358-X","article-title":"High efficiency transformation by direct microinjection of DNA into cultured mammalian cells","volume":"22","author":"Capecchi","year":"1980","journal-title":"Cell"},{"key":"2021121023214865000_cei13517-bib-0180","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.vaccine.2005.01.036","article-title":"The development of vaccines against SARS corona virus in mice and SCID-PBL\/hu mice","volume":"23","author":"Okada","year":"2005","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0181","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/CVI.00261-08","article-title":"Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice","volume":"16","author":"Lu","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"2021121023214865000_cei13517-bib-0182","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1128\/CVI.00019-07","article-title":"Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice","volume":"14","author":"Hu","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"2021121023214865000_cei13517-bib-0183","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0184","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0185","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"key":"2021121023214865000_cei13517-bib-0186","article-title":"Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model","author":"Patel","year":"2020","journal-title":"bioRxiv"},{"key":"2021121023214865000_cei13517-bib-0187","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/iub.1625","article-title":"RNA sensors of the innate immune system and their detection of pathogens","volume":"69","author":"Chen","year":"2017","journal-title":"IUBMB Life"},{"key":"2021121023214865000_cei13517-bib-0188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","article-title":"Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response","volume":"15","author":"Edwards","year":"2017","journal-title":"J Transl Med"},{"key":"2021121023214865000_cei13517-bib-0189","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design","volume":"198","author":"Pepini","year":"2017","journal-title":"J Immunol"},{"key":"2021121023214865000_cei13517-bib-0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"2021121023214865000_cei13517-bib-0191","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol Ther"},{"key":"2021121023214865000_cei13517-bib-0192","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nature09267","article-title":"Mammalian microRNAs predominantly act to decrease target mRNA levels","volume":"466","author":"Guo","year":"2010","journal-title":"Nature"},{"key":"2021121023214865000_cei13517-bib-0193","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1093\/nar\/gki1012","article-title":"AU-rich elements and associated factors: are there unifying principles?","volume":"33","author":"Barreau","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"2021121023214865000_cei13517-bib-0194","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"2021121023214865000_cei13517-bib-0195","article-title":"SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness","author":"Corbett","year":"2020","journal-title":"bioRxiv"},{"key":"2021121023214865000_cei13517-bib-0196","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"2021121023214865000_cei13517-bib-0197","article-title":"A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice","volume-title":"Immunity","author":"Laczk\u00f3","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0198","article-title":"Phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age. Interim report","author":"Mulligan","year":"2020","journal-title":"medRxiv"},{"key":"2021121023214865000_cei13517-bib-0199","doi-asserted-by":"crossref","DOI":"10.1101\/2020.07.17.20140533","article-title":"Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine","volume-title":"Medrxiv","author":"Sahin","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0200","doi-asserted-by":"crossref","DOI":"10.1101\/2020.08.17.20176651","article-title":"RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study","volume-title":"Medrxiv","author":"Walsh","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0201","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","article-title":"Adjuvanted influenza vaccines","volume":"14","author":"Tregoning","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2021121023214865000_cei13517-bib-0202","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front Immunol"},{"key":"2021121023214865000_cei13517-bib-0203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2008.04.036","article-title":"Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens","volume":"364","author":"Perrie","year":"2008","journal-title":"Int J Pharm"},{"key":"2021121023214865000_cei13517-bib-0204","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"2021121023214865000_cei13517-bib-0205","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0264-410X(02)00548-0","article-title":"Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs","volume":"21","author":"Hogarth","year":"2003","journal-title":"Vaccine"},{"key":"2021121023214865000_cei13517-bib-0206","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.4161\/hv.24702","article-title":"Tolerability of intramuscular and intradermal delivery by CELLECTRA(\u00ae) adaptive constant current electroporation device in healthy volunteers","volume":"9","author":"Diehl","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2021121023214865000_cei13517-bib-0207","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.3389\/fimmu.2019.02911","article-title":"The safety and immunogenicity of GTU\u00aeMultiHIV DNA vaccine delivered by transcutaneous and intramuscular injection with or without electroporation in HIV-1 positive subjects on suppressive ART","volume":"10","author":"Haidari","year":"2019","journal-title":"Front Immunol"},{"key":"2021121023214865000_cei13517-bib-0208","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"key":"2021121023214865000_cei13517-bib-0209","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059340","article-title":"DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial","volume":"8","author":"Graham","year":"2013","journal-title":"PLOS ONE"},{"key":"2021121023214865000_cei13517-bib-0210","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","article-title":"BCG-induced trained immunity: can it offer protection against COVID-19?","volume":"20","author":"O'Neill","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2021121023214865000_cei13517-bib-0211","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.abc4262","article-title":"Can existing live vaccines prevent COVID-19?","volume":"368","author":"Chumakov","year":"2020","journal-title":"Science"},{"key":"2021121023214865000_cei13517-bib-0212","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00907-20","article-title":"Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection?","volume":"11","author":"Fidel","year":"2020","journal-title":"mBio"},{"key":"2021121023214865000_cei13517-bib-0213","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/infdis\/136.2.171","article-title":"Nonspecific protection of mice against influenza virus infection by local or systemic immunization with bacille Calmette\u2013Guerin","volume":"136","author":"Spencer","year":"1977","journal-title":"J Infect Dis"},{"key":"2021121023214865000_cei13517-bib-0214","doi-asserted-by":"crossref","first-page":"109707","DOI":"10.1016\/j.mehy.2020.109707","article-title":"Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic?","author":"Gursel","year":"2020","journal-title":"Med Hypoth"},{"key":"2021121023214865000_cei13517-bib-0215","doi-asserted-by":"crossref","first-page":"17720","DOI":"10.1073\/pnas.2008410117","article-title":"BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)","volume":"30","author":"Escobar","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021121023214865000_cei13517-bib-0216","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2021121023214865000_cei13517-bib-0217","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2021121023214865000_cei13517-bib-0218","volume-title":"Government launches vaccine taskforce to combat coronavirus 2020","author":"UKGov"},{"key":"2021121023214865000_cei13517-bib-0219","volume-title":"Moderna Manufacturing: Why Norwood?","author":"Moderna","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0220","volume-title":"Standardization of vaccines for coronavirus disease (COVID-19)","author":"World Health Organization","year":"2020"},{"key":"2021121023214865000_cei13517-bib-0221","volume-title":"Successful Ebola vaccine provides 100% protection in trial","author":"NatureNews","year":"2015"},{"key":"2021121023214865000_cei13517-bib-0222","volume-title":"Roadmap for introduction and roll-out of Merck rVSV-ZEBOV","author":"WHO","year":"2019"},{"key":"2021121023214865000_cei13517-bib-0223","volume-title":"Major milestone for WHO-supported Ebola vaccine","author":"World Health Organization","year":"2019"},{"key":"2021121023214865000_cei13517-bib-0224","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/jech-2016-208141","article-title":"Return on investment of public health interventions: a systematic review","volume":"71","author":"Masters","year":"2017","journal-title":"J Epidemiol Community Health"},{"key":"2021121023214865000_cei13517-bib-0225","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(20)31873-0","article-title":"Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access","volume":"396","author":"Phelan","year":"2020","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13517","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13517","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/202\/2\/162\/41635580\/cei13517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/202\/2\/162\/41635580\/cei13517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T02:06:10Z","timestamp":1723601170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/202\/2\/162\/6402968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,18]]},"references-count":225,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,18]]},"published-print":{"date-parts":[[2020,10,30]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13517","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,10,18]]}}}